Literature DB >> 20858850

Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.

Sonia P Li1, N Jane Taylor, Andreas Makris, Mei-Lin W Ah-See, Mark J Beresford, J James Stirling, James A d'Arcy, David J Collins, Anwar R Padhani.   

Abstract

PURPOSE: To investigate the histopathologic and dynamic magnetic resonance (MR) imaging correlates of intrinsic susceptibility-weighted (ISW) MR imaging in patients with primary human breast adenocarcinoma and to assess the relationship between baseline transverse relaxation rate (R2*) and T2* relaxivity change (ΔR2*) and the response to neoadjuvant chemotherapy (NAC).
MATERIALS AND METHODS: Institutional ethics approval and informed consent were obtained. Between September 2001 and January 2008, 83 women (median age, 46 years; age range, 26-72 years) with breast cancer were recruited to undergo dynamic contrast medium-enhanced (DCE), dynamic susceptibility contrast-enhanced (DSC), and ISW MR imaging before and after two cycles of NAC. After excluding necrotic, infiltrating, and invasive lobular carcinomas, 31 patients were available for baseline assessment and 27 were available for response assessment. Transfer constant, leakage space, rate constant, initial area under the gadolinium concentration-time curve at 60 seconds, relative blood volume (rBV), relative blood flow (rBF), and R2* were calculated. Relationships between baseline R2* and histopathologic variables (tumor grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor 2 status), tumor size, and dynamic MR imaging parameters were sought. Baseline adenocarcinoma R2* (n = 31) and ΔR2* (n = 27) were correlated with final pathologic response.
RESULTS: Inverse correlations between baseline R2* and rBV (ρ = -0.48, P = .013) and rBF (ρ = -0.44, P = .024) were found, but not after NAC. No relationships were observed between baseline R2* and other kinetic imaging parameters, histopathologic characteristics, or tumor size (P > .05). Baseline R2* values were lower in tumors than in normal breast tissue (31.8 sec(-1) vs 36.2 sec(-1), P = .017) but not after NAC. Increases in R2* were observed after treatment (31.1 sec(-1) vs 34.8 sec(-1), P = .006), with larger increases correlating with pathologic response. ΔR2* was not as effective as DCE or DSC MR imaging parameters in the prediction of response.
CONCLUSION: R2* is influenced by blood volume in untreated breast adenocarcinomas. Increases in R2* after two cycles of NAC correlate with pathologic response. Therapy-induced uncoupling of the relationship between R2* and rBV and rBF is consistent with responding tumors becoming hypoxic early during treatment. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10100421/-/DC1. © RSNA, 2010

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858850     DOI: 10.1148/radiol.10100421

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

Review 1.  Clinical implications of skeletal muscle blood-oxygenation-level-dependent (BOLD) MRI.

Authors:  Sasan Partovi; Sasan Karimi; Bjoern Jacobi; Anja-Carina Schulte; Markus Aschwanden; Lisa Zipp; John K Lyo; Christof Karmonik; Matthias Müller-Eschner; Rolf W Huegli; Georg Bongartz; Deniz Bilecen
Journal:  MAGMA       Date:  2012-02-29       Impact factor: 2.310

Review 2.  Functional MRI and CT biomarkers in oncology.

Authors:  J M Winfield; G S Payne; N M deSouza
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-13       Impact factor: 9.236

Review 3.  Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.

Authors:  R Prevos; M L Smidt; V C G Tjan-Heijnen; M van Goethem; R G Beets-Tan; J E Wildberger; M B I Lobbes
Journal:  Eur Radiol       Date:  2012-09-16       Impact factor: 5.315

Review 4.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

5.  MRI and ¹⁸F-FDG PET/CT in monitoring the response to neoadjuvant chemotherapy: is it necessary to appropriately select the patients?

Authors:  Laura Evangelista; Domenico Ruggieri; Luigi Pescarini; Giorgio Saladini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08       Impact factor: 9.236

6.  BOLD-MRI of breast invasive ductal carcinoma: correlation of R2* value and the expression of HIF-1α.

Authors:  Min Liu; Xiaojuan Guo; Shuangkun Wang; Mulan Jin; Ying Wang; Jie Li; Jun Liu
Journal:  Eur Radiol       Date:  2013-07-09       Impact factor: 5.315

7.  Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients?

Authors:  Boram Yi; Doo Kyoung Kang; Dukyong Yoon; Yong Sik Jung; Ku Sang Kim; Hyunee Yim; Tae Hee Kim
Journal:  Eur Radiol       Date:  2014-02-21       Impact factor: 5.315

Review 8.  The role of functional imaging in the era of targeted therapy of renal cell carcinoma.

Authors:  Margarita Braunagel; Anno Graser; Maximilian Reiser; Mike Notohamiprodjo
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

Review 9.  Multiparametric MR Imaging of Breast Cancer.

Authors:  Habib Rahbar; Savannah C Partridge
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

10.  Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?

Authors:  David K Woolf; N Jane Taylor; Andreas Makris; Nina Tunariu; David J Collins; Sonia P Li; Mei-Lin Ah-See; Mark Beresford; Anwar R Padhani
Journal:  Br J Radiol       Date:  2016-05-17       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.